SAN DIEGO, May  05, 2026  (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of GeneDx Holdings Corp. (NASDAQ:WGS). The investigation focuses on GeneDx&#39;s executive officers

GeneDx Holdings Corp. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

GeneDx Faces Investigation Amidst Revenue Guidance Cut and Stock Decline

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>SAN DIEGO, May  05, 2026  (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of GeneDx Holdings Corp. (NASDAQ:WGS). The investigation focuses on GeneDx&amp;#39;s executive officers</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>GeneDx Holdings Corp. is under investigation by Johnson Fistel for potential securities law violations after a significant revenue guidance reduction. The firm&#039;s Q1 2026 results were below expectations, leading to a sharp decline in the stock price, raising concerns for investors about future performance and compliance.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Johnson Fistel investigates potential claims for GeneDx investors.</li><li>GeneDx reports Q1 2026 revenue of $102.3 million and reduced guidance.</li><li>Exome and genome revenue growth slowed to 27% year-over-year.</li><li>Stock price declined after earnings call, impacting investor sentiment.</li><li>Investigation focuses on compliance with federal securities laws.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>GeneDx Holdings Corp. (WGS)</strong>: Facing investigation which could exacerbate stock volatility.</li><li><strong>Johnson Fistel, PLLP</strong>: Legal firm initiating investigation indicates serious investor concerns.</li></ul>
  </section>

  <section data-block="category">
    <h3>Legal</h3>
    <p>This news falls under &#039;Legal&#039; category as it pertains to an investigation regarding compliance with federal securities laws, potentially impacting investor confidence and stock performance.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>GeneDx reduced its full-year 2026 revenue guidance by up to $80 million.</li><li>Q1 2026 revenue missed estimates by approximately $12 million.</li><li>Share price decline reflects investor concerns post-earnings call.</li><li>Ongoing investigation may lead to investor lawsuits and further volatility.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>GeneDx&#039;s Q1 2026 total revenue was $102.3 million.</li><li>Exome and genome revenue growth was only 27% year-over-year.</li><li>Full-year revenue guidance now at $475-$490 million, previously $540-$555 million.</li><li>Test volume grew 34% year-over-year despite lower revenue growth.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Consider shorting WGS over the next quarter due to regulatory risks and declining guidance.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p align="left">SAN DIEGO, May  05, 2026  (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of GeneDx Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/WGS">WGS</a>). The investigation focuses on GeneDx's executive officers and whether investor losses may be recovered under federal securities laws.</p>  <p><strong>What if I purchased GeneDx securities?</strong><br></br>If you purchased GeneDx securities and suffered losses on your investment, join our investigation now: <a href="https://www.globenewswire.com/Tracker?data=mx2PmJ5KOo_vo7jGGV3TxbJwaLBksa9wflA8j7VlDn50-xqhgl3D1ndNoDhY3_SxOaQECC-wHhJO0ncuspNiDegfyvVlI_z6K8TDlWK3UKCRRuoTNKs2NSwIDNnZ3GAsabvOUjyrgMCKFzCBxbhTJBbKRGXa6E1xaQ7UmY3ezrudX-6zp-Oczzd1pKnlmbkk" rel="nofollow" target="_blank">Click here to join the investigation</a>.</p>  <p>Or for more information, contact Jim Baker at <a href="mailto:jimb@johnsonfistel.com">jimb@johnsonfistel.com</a> or (619) 814-4471.</p>  <p>There is no cost or obligation to you.</p>  <p><strong>Background of the investigation</strong><br></br>On May 4, 2026, GeneDx reported its first quarter 2026 financial results and updated its full-year outlook. Among other things, the Company disclosed total revenue of $102.3 million, exome and genome revenue of $90.6 million, and exome and genome test volume growth of 34% year-over-year.</p>  <p>Despite this strong volume growth, GeneDx disclosed that exome and genome revenue increased only 27% year-over-year. The Company also reduced its full-year 2026 revenue guidance to $475 million to $490 million, compared to prior guidance of $540 million to $555 million, and reduced its expected growth in exome and genome revenue to at least 20%, compared to prior guidance of 33% to 35%.</p>  <p>During the Company's earnings call, GeneDx further disclosed that total revenue was approximately $12 million below expectations, including approximately $5.5 million due to a lower-than-expected blended average reimbursement rate for exome and genome testing, and approximately $6.5 million due to softer-than-expected performance from non-core business lines.</p>  <p>Following this disclosure, GeneDx's stock price declined sharply, damaging investors.</p>  <p>In light of this disclosure, Johnson Fistel is investigating whether GeneDx complied with the federal securities laws. If you suffered losses from your investment in GeneDx stock, contact Johnson Fistel.</p>  <p><strong>About Johnson Fistel, PLLP &#x7C; Securities Fraud &amp; Investor Rights</strong><br></br>Johnson Fistel, PLLP is a nationally recognized shareholder-rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits and also assists foreign investors who purchased shares on U.S. exchanges. To learn more, visit <a href="https://www.globenewswire.com/Tracker?data=LDolDvqJ0zzWuVBkBsP4BLpEsqtYgFFiWfCWENTsMYpd_cg_La7aeEJ2d50QI4qHs9UtYirMt01Md93FBmMg-n-uVg1u6_NJ_CuvSAnSta8=" rel="nofollow" target="_blank">www.johnsonfistel.com</a>.</p>  <p><strong>Achievements</strong><br></br>In 2024, Johnson Fistel was ranked among the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services, reflecting the firm's effectiveness in advocating for investors and recovering approximately $90,725,000 for clients in cases where it served as lead or co-lead counsel.</p>  <p>Attorney advertising.<br></br>Past results do not guarantee future outcomes.<br></br>Services may be performed by attorneys in any of our offices.<br></br>Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.</p>  <p><strong>Contact</strong><br></br>Johnson Fistel, PLLP<br></br>501 W. Broadway, Suite 800<br></br>San Diego, CA 92101<br></br>James Baker, Investor Relations – or – Frank J. Johnson, Esq.<br></br>(619) 814-4471 &#x7C; <a href="mailto:jimb@johnsonfistel.com">jimb@johnsonfistel.com</a> &#x7C; <a href="mailto:fjohnson@johnsonfistel.com">fjohnson@johnsonfistel.com</a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTcxMzI2NiM3NTgyOTI2IzIxODE3ODk="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/NjE2ZmFjOGMtNDhlYy00NTYwLWE4NjctM2IxMDE5Zjg3NjhkLTExOTMzNTgtMjAyNi0wNS0wNS1lbg==/tiny/Johnson-Fistel-PLLP.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/bb2e6cf6-9d53-4d2e-a5d2-759cdd3b516c"><img src="https://ml.globenewswire.com/media/bb2e6cf6-9d53-4d2e-a5d2-759cdd3b516c/small/johnson-fistel-jpg.jpg" border="0" width="150" height="150" alt="Primary Logo"></img></a></p>

GeneDx Holdings Corp. is under investigation by Johnson Fistel for potential securities law violations after a significant revenue guidance reduction. The firm's Q1 2026 results were below expectations, leading to a sharp decline in the stock price, raising concerns for investors about future performance and compliance.

GeneDx Holdings Corp. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Legal

Related News